SGMO

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a clinical-stage biotechnology company founded in 1995 and headquartered in Brisbane, California. The company went public in 2000 and has evolved from its original focus as Sangamo BioSciences into a genomic medicine company specializing in gene therapy, cell therapy, genome editing, and genome regulation. Sangamo has built a portfolio of proprietary platform technologies centered around zinc finger proteins and has established strategic partnerships with major pharmaceutical companies including Pfizer, Genentech, Biogen, and others. The company is currently advancing multiple clinical-stage programs targeting rare genetic diseases and neurological disorders.